Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Povorcitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte Povorcitinib Shows 54-Week Data In HS At AAD
    Incyte Povorcitinib Shows 54-Week Data In HS At AAD

    28 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260328441699/en/Incyte-Announces-New-Positive-54-Week-Late-Breaking-Data-for-Povorcitinib-in-Hidradenitis-Suppurativa-at-the-2026-American-Academy-of-Dermatology-AAD-Annual-Meeting

    BUSINESSWIRE
    28 Mar 2026
    Share Share
    Incyte reports positive results from Phase 3 trials of Povorcitinib
    Incyte reports positive results from Phase 3 trials of Povorcitinib

    17 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250317947508/en/Incyte-Announces-Positive-Topline-Results-From-Two-Phase-3-Clinical-Trials-of-Povorcitinib-in-Patients-With-Hidradenitis-Suppurativa

    BUSINESSWIRE
    17 Mar 2025
    Share Share
    CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China
    CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China

    04 Apr 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24039/cms-and-incyte-collaborate-to-develop-vitiligo-drug-povorcitinib-in-china-and-southeast-asia.html

    BIOSPECTRUM ASIA
    04 Apr 2024
    Share Share
    Incyte and CMS Announce Collab and License Agreement for Povorcitinib in Asia
    Incyte and CMS Announce Collab and License Agreement for Povorcitinib in Asia

    01 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240401280916/en

    BUSINESSWIRE
    01 Apr 2024
    Share Share
    Incyte's oral Dupixent rival hits in midphase skin disease trial
    Incyte's oral Dupixent rival hits in midphase skin disease trial

    12 Mar 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/incyte-itching-piece-dupixents-market-hits-goals-midphase-skin-disease-trial

    FIERCE BIOTECH
    12 Mar 2024
    Share Share
    Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib
    Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib

    10 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240310275231/en

    BUSINESSWIRE
    10 Mar 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.